The GBMRP recognizes the critical need for improved resources to advance the field of glioblastoma research and improve outcomes for individuals with glioblastoma. The FY24 GBMRP Resource Development Award supports product-driven effort focused on the advancement of preclinical model systems (in vitro and in vivo) that need further development, characterization, validation, or standardization. Studies may include, but are not limited to, the development or characterization of animal models, preclinical autologous human immune models, organoids, or patient-derived xenografts (PDXs). Proposals should include experiments that demonstrate the research tool or model improves preclinical biological relevance. Models recapitulating glioblastoma pathobiology, particularly as it relates to tumor recurrence, late-stage disease, tumor microenvironment and/or immunity component are strongly encouraged. Projects that focus primarily on investigating the pathophysiology of glioblastoma, without consideration of disease model development or characterization, are not within the scope of this funding opportunity.Key Aspects of the Resource Development Award Preliminary data is required. Applicants must demonstrate proof-of-concept data in an existing preclinical model system that the research team is looking to further develop, characterize, validate, or standardize. A Resource Distribution Plan is required. The Resource Distribution Plan should describe the means by which the fully developed resource will be made available to the scientific and/or clinical community at reasonable or appropriate administrative costs.